Vitamin D deficiency and persistent proteinuria among HIV-infected and uninfected injection drug users

AIDS

Volumn 26, Issue 3, 2012, Pages 295-302

  Estrella, Michelle M ^a   Kirk, Gregory D ^a,b   Mehta, Shruti H ^b   Brown, Todd T ^a   Fine, Derek M ^a   Atta, Mohamed G ^a   Lucas, Gregory M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

diabetes; HIV; injection drug use; proteinuria; vitamin D deficiency

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; PROTEIN; VITAMIN D;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; VITAMIN D DEFICIENCY;

AIDS-ASSOCIATED NEPHROPATHY; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HIV-1; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; QUESTIONNAIRES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; VITAMIN D DEFICIENCY;

EID: 84855353677     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834f33a2     Document Type: Article

References (40)

1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
2. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121:651-658.
3. Yanik EL, Lucas GM, Vlahov D, Kirk GD, Mehta SH. HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol 2010; 5:1836-1843.
4. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61:195-202. (Pubitemid 34075147)
5. Adeyemi OM, Agniel D, French AL, Tien P, Weber K, Glesby MJ, et al. Vitamin D deficiency in HIV-infected and un-infected women in the US. J Acquir Immune Defic Syndr 2011.
6. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitaminDLevels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52:396-405.
7. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238. (Pubitemid 34787360)
8. Alvarez JA, Ashraf AP, Hunter GR, Gower BA. Serum 25-hydroxyvitamin D and parathyroid hormone are independent determinants of whole-body insulin sensitivity in women and may contribute to lower insulin sensitivity in African Americans. Am J Clin Nutr 2010; 92:1344-1349.
9. Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A. Vitamin d deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 2011; 21:295-302.
10. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 2010; 21:966-973.
11. Artaza JN, Norris KC. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 2009; 200:207-221.
12. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009; 20:2631-2639.
13. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50:69-77. (Pubitemid 46962855)
14. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54:647-652.
15. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376:1543-1551.
16. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109:75-100. (Pubitemid 23095616)
17. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147.
18. Hollis BW, Napoli JL. Improved radioimmunoassay for vitamin D and its use in assessing vitamin D status. Clin Chem 1985; 31:1815-1819. (Pubitemid 16012541)
19. Yetley EA, Pfeiffer CM, Schleicher RL, Phinney KW, Lacher DA, Christakos S, et al. NHANES monitoring of serum 25-hydroxyvitamin D: a roundtable summary. J Nutr 2010; 140:2030S-2045S.
20. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009; 169:626-632.
21. Salter ML, Lau B, Go VF, Mehta SH, Kirk GD. HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis 2011; 53:1256-1264.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
23. Estrella MM, Parekh RS, Abraham A, Astor BC, Szczech LA, Anastos K, et al. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:217-220.
24. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010; 24:387-394.
25. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-546. (Pubitemid 38365883)
26. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG. HIVinfected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009; 23:2143-2149.
27. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008; 105:15896-15901.
28. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 2010; 77:1000-1009.
29. Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ. The reninangiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 2003; 20:607-621. (Pubitemid 36966554)
30. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003; 14:274-281. (Pubitemid 36992197)
31. Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57:590-600. (Pubitemid 30430651)
32. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
33. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996; 98:1966-1970. (Pubitemid 26376283)
34. Fornoni A. Proteinuria, the podocyte, and insulin resistance. N Engl J Med 2010; 363:2068-2069.
35. Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010; 12:329-340.
36. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286:F526-F533. (Pubitemid 38233647)
37. Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 2011.
38. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008; 74:1343-1353.
39. Li Y, Spataro BC, Yang J, Dai C, Liu Y. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68:1500-1510. (Pubitemid 43173380)
40. Yadav A, Vallabu S, Kumar D, Ding G, Charney DN, Chander PN, et al. HIVAN phenotype: consequence of epithelial mesenchymal transdifferentiation. Am J Physiol Renal Physiol 2010; 298:F734-F744.